{"filing":{"accession_number":"0001213900-26-069902","cik":"0001937993","ticker":"CVKD","company_name":"Cadrenal Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"ea0295234-8k_cadrenal.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026069902/ea0295234-8k_cadrenal.htm"},"events":[{"id":11730,"run_id":10311,"accession_number":"0001213900-26-069902","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Cadrenal announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the FDA for tecarfarin in Kawasaki disease, which if granted would make the company eligible for a Priority Review Voucher valued at $180–$205 million. The company also disclosed a dual-track portfolio strategy representing a material strategic and regulatory development affecting investor expectations around value creation and capital efficiency.","company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8391,"accession_number":"0001213900-26-069902","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Cadrenal announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the FDA for tecarfarin in Kawasaki disease, which if granted would make the company eligible for a Priority Review Voucher valued at $180–$205 million. The company also disclosed a dual-track portfolio strategy. While this is a material strategic and regulatory development affecting investor expectations around value creation and capital efficiency, it does not fit neatly into the more specific event categories (it is not an earnings release, M\u0026A activity, executive change, impairment, or litigation). The disclosure is forward-looking and contingent on FDA approval, but the announcement of the RPDD filing plan and the articulation of a capital-efficient dual-track strategy represent material portfolio and business development disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T13:03:11.552285+00:00","company_name":"","ticker":null,"filing_date":""},{"id":8392,"accession_number":"0001213900-26-069902","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Cadrenal announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the FDA for tecarfarin in Kawasaki disease, with potential eligibility for a Priority Review Voucher valued at $180–$205 million if approved. While this is a significant regulatory and strategic milestone, it does not fit neatly into the standard 8-K taxonomy—it is neither a completed M\u0026A transaction, an executive change, a restatement, nor a going-concern disclosure. The announcement of a dual-track portfolio strategy and participation in BIO 2026 are material corporate developments that would affect investor assessment of the company's strategic direction and value creation potential, warranting classification as \"other_material.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T13:03:11.552285+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8391,"accession_number":"0001213900-26-069902","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Cadrenal announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the FDA for tecarfarin in Kawasaki disease, which if granted would make the company eligible for a Priority Review Voucher valued at $180–$205 million. The company also disclosed a dual-track portfolio strategy. While this is a material strategic and regulatory development affecting investor expectations around value creation and capital efficiency, it does not fit neatly into the more specific event categories (it is not an earnings release, M\u0026A activity, executive change, impairment, or litigation). The disclosure is forward-looking and contingent on FDA approval, but the announcement of the RPDD filing plan and the articulation of a capital-efficient dual-track strategy represent material portfolio and business development disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T13:03:11.552285+00:00","company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","filing_date":"2026-06-18"},{"id":8392,"accession_number":"0001213900-26-069902","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Cadrenal announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the FDA for tecarfarin in Kawasaki disease, with potential eligibility for a Priority Review Voucher valued at $180–$205 million if approved. While this is a significant regulatory and strategic milestone, it does not fit neatly into the standard 8-K taxonomy—it is neither a completed M\u0026A transaction, an executive change, a restatement, nor a going-concern disclosure. The announcement of a dual-track portfolio strategy and participation in BIO 2026 are material corporate developments that would affect investor assessment of the company's strategic direction and value creation potential, warranting classification as \"other_material.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T13:03:11.552285+00:00","company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","filing_date":"2026-06-18"}]}